Skip to main content

Blood and urine tests developed to indicate autism in children

• Test believed to be the first of its kind

• Link found between autism and damage to proteins in blood plasma

• Could lead to earlier diagnosis of the condition

New tests which can indicate autism in children have been developed by researchers at the University of Warwick.

The academic team who conducted the international research believe that their new blood and urine tests which search for damage to proteins are the first of their kind.

The tests could lead to earlier detection of autism spectrum disorders (ASD) and consequently children with autism could be given appropriate treatment much earlier in their lives. ASDs are defined as developmental disorders mainly affecting social interaction and they can include a wide spectrum of behavioural problems. These include speech disturbances, repetitive and/or compulsive behaviour, hyperactivity, anxiety, and difficulty to adapt to new environments, some with or without cognitive impairment. Since there is a wide range of ASD symptoms diagnosis can be difficult and uncertain, particularly at the early stages of development.

The paper “Advanced glycation endproducts, dityrosine, and arginine transporter dysfunction in autism—a source of biomarkers for clinical diagnosis” has been published in Molecular Autism. The team was led by Dr Naila Rabbani, Reader of Experimental Systems Biology at the University of Warwick who said: “Our discovery could lead to earlier diagnosis and intervention.”

“We hope the tests will also reveal new causative factors. With further testing we may reveal specific plasma and urinary profiles or “fingerprints” of compounds with damaging modifications. This may help us improve the diagnosis of ASD and point the way to new causes of ASD.”

The team which is based at the University’s Warwick Medical School involves academics at the University of Warwick’s Warwick Systems Biology group, the University of Birmingham, the University of Bologna, the Institute of Neurological Sciences, Bologna, and the Don Carlo Gnocchi Foundation ONLUS. They found a link between ASD and damage to proteins in blood plasma by oxidation and glycation – processes where reactive oxygen species (ROS) and sugar molecules spontaneously modify proteins. They found the most reliable of the tests they developed was examining protein in blood plasma where, when tested, children with ASD were found to have higher levels of the oxidation marker dityrosine (DT) and certain sugar-modified compounds called “advanced glycation endproducts” (AGEs). Genetic causes have been found in 30–35% of cases of ASD and the remaining 65–70% of cases are thought to be caused by a combination of environmental factors, multiple mutations, and rare genetic variants. However the research team also believe that the new tests could reveal yet to be identified causes of ASD.

The team’s research also confirmed the previously held belief that mutations of amino acid transporters are a genetic variant associated with ASD. The Warwick team worked with collaborators at the University of Bologna, Italy, who recruited locally 38 children who were diagnosed as having with ASD (29 boys and nine girls) and a control group of 31 children (23 boys and eight girls) between the ages of five and 12. Blood and urine samples were taken from the children for analysis.

The University of Warwick team discovered that there were chemical differences between the two groups. Working with a further collaborator at the University of Birmingham, the changes in multiple compounds were combined together using artificial intelligence algorithms techniques to develop a mathematical equation or “algorithm” to distinguish between ASD and controls. The outcome was a diagnostic test better than any method currently available.

The next steps are to repeat the study with further groups of children to confirm the good diagnostic performance and to assess if the test can identify ASD at very early stages assess if treatments are working.

19 February 2018


Notes to Editors Title: Advanced glycation endproducts, dityrosine, and arginine transporter dysfunction in autism—a source of biomarkers for clinical diagnosis Published in: Molecular Autism

DOI 10.1186/s13229-017-0183-3

Authors:

Attia Anwar, Warwick Medical School, University of Warwick Provvidenza Maria Abruzzo, Department of Experimental, Diagnostic and Specialty Medicine, School of Medicine, University of Bologna; Don Carlo Gnocchi Foundation ONLUS, IRCCS “S. Maria Nascente”, Milan Sabah Pasha, Warwick Medical School, University of Warwick Kashif Rajpoot, Department of Computer Science, University of Birmingham, Alessandra Bolotta, Department of Experimental, Diagnostic and Specialty Medicine, School of Medicine, University of Bologna; Don Carlo Gnocchi Foundation ONLUS, IRCCS “S. Maria Nascente”, Milan; Warwick Systems Biology, University of Warwick, Clinical Sciences Research Laboratories, University Hospital, Coventry Alessandro Ghezzo, Department of Experimental, Diagnostic and Specialty Medicine, School of Medicine, University of Bologna, Marina Marini, Department of Experimental, Diagnostic and Specialty Medicine, School of Medicine, University of Bologna; Don Carlo Gnocchi Foundation ONLUS, IRCCS “S. Maria Nascente”, Milan, Annio Posar, Child Neurology and Psychiatry Unit, IRCCS Institute of Neurological Sciences, Bologna; Department of Biomedical and Neuromotor Sciences, University of Bologna Paola Visconti Child Neurology and Psychiatry Unit, IRCCS Institute of Neurological Sciences, Bologna Paul J. Thornalley, Warwick Medical School, University of Warwick; Warwick Systems Biology, University of Warwick, Clinical Sciences Research Laboratories, University Hospital, Coventry Naila Rabbani, Warwick Medical School, University of Warwick; Warwick Systems Biology, University of Warwick, Clinical Sciences Research Laboratories, University Hospital, Coventry; Research Technology Platform–Proteomics, University of Warwick; AGEomics and Systems Biology Research Group, Warwick Systems Biology, University of Warwick, University Hospital, Coventry

This work received the following funding: Naila Rabbani - Warwick Impact Fund; Marina Marini - Fondazione del Monte di Bologna e Ravenna, Italy; Fondazione Nando Peretti, Rome, Italy

For further details contact
Nicola Jones, Media Relations Manager University of Warwick
07920531221 or N.Jones.1@warwick.ac.uk